Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristine A Frerichs

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Frontiers in Immunology|May 15, 2026
Modulating CD38 enzymatic activity during antibody-based immunotherapy in multiple myeloma: a basic science perspectiveAlberto L Horenstein, Kristine A Frerichs, Angelo C Faini, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|November 16, 2013
Inconclusive evidence for allergic rhinitis to predict a prolonged or chronic course of acute rhinosinusitisKristine A Frerichs, Gea Nigten, Kalynda Romeijn, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 6, 2018
Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab TreatmentKristine A Frerichs, Patricia W C Bosman, Inger S Nijhof, et al.
Journal of Translational Autoimmunity|August 4, 2020
CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patientsKristine A Frerichs, Christie P M Verkleij, Patricia W C Bosman, et al.
Journal of Clinical Medicine|October 13, 2021
Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple MyelomaMashhour Hosny, Christie P M Verkleij, Jort van der Schans, et al.
Cancers|December 16, 2020
Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive MalignanciesChristie P M Verkleij, Amy Jhatakia, Marloes E C Broekmans, et al.
Cancers|June 2, 2021
Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma PatientsKristine A Frerichs, Christie P M Verkleij, Meletios A Dimopoulos, et al.
Oncotarget|November 23, 2020
T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myelomaChristie P M Verkleij, Kristine A Frerichs, Marloes Broekmans, et al.
Hemasphere|September 9, 2020
Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple MyelomaMarina Zajec, Kristine A Frerichs, Martijn M van Duijn, et al.
Haematologica|September 28, 2019
Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patientsKristine A Frerichs, Patricia W C Bosman, Jeroen F van Velzen, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Frontiers in Immunology|May 15, 2026
Modulating CD38 enzymatic activity during antibody-based immunotherapy in multiple myeloma: a basic science perspectiveAlberto L Horenstein, Kristine A Frerichs, Angelo C Faini, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|November 16, 2013
Inconclusive evidence for allergic rhinitis to predict a prolonged or chronic course of acute rhinosinusitisKristine A Frerichs, Gea Nigten, Kalynda Romeijn, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 6, 2018
Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab TreatmentKristine A Frerichs, Patricia W C Bosman, Inger S Nijhof, et al.
Journal of Translational Autoimmunity|August 4, 2020
CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patientsKristine A Frerichs, Christie P M Verkleij, Patricia W C Bosman, et al.
Journal of Clinical Medicine|October 13, 2021
Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple MyelomaMashhour Hosny, Christie P M Verkleij, Jort van der Schans, et al.
Cancers|December 16, 2020
Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive MalignanciesChristie P M Verkleij, Amy Jhatakia, Marloes E C Broekmans, et al.
Cancers|June 2, 2021
Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma PatientsKristine A Frerichs, Christie P M Verkleij, Meletios A Dimopoulos, et al.
Oncotarget|November 23, 2020
T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myelomaChristie P M Verkleij, Kristine A Frerichs, Marloes Broekmans, et al.
Hemasphere|September 9, 2020
Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple MyelomaMarina Zajec, Kristine A Frerichs, Martijn M van Duijn, et al.
Haematologica|September 28, 2019
Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patientsKristine A Frerichs, Patricia W C Bosman, Jeroen F van Velzen, et al.
Pageof 2